JP2010510804A - ２型糖尿病の遺伝的感受性変異体 - Google Patents
２型糖尿病の遺伝的感受性変異体 Download PDFInfo
- Publication number
- JP2010510804A JP2010510804A JP2009538856A JP2009538856A JP2010510804A JP 2010510804 A JP2010510804 A JP 2010510804A JP 2009538856 A JP2009538856 A JP 2009538856A JP 2009538856 A JP2009538856 A JP 2009538856A JP 2010510804 A JP2010510804 A JP 2010510804A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- diabetes
- marker
- allele
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 408
- 238000000034 method Methods 0.000 claims abstract description 234
- 239000003814 drug Substances 0.000 claims abstract description 77
- 230000001965 increasing effect Effects 0.000 claims abstract description 67
- 229940079593 drug Drugs 0.000 claims abstract description 39
- 238000011282 treatment Methods 0.000 claims abstract description 36
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 34
- 238000003745 diagnosis Methods 0.000 claims abstract description 22
- 230000003247 decreasing effect Effects 0.000 claims abstract description 18
- 239000003550 marker Substances 0.000 claims description 380
- 108700028369 Alleles Proteins 0.000 claims description 344
- 102000054766 genetic haplotypes Human genes 0.000 claims description 302
- 150000007523 nucleic acids Chemical class 0.000 claims description 193
- 102000039446 nucleic acids Human genes 0.000 claims description 178
- 108020004707 nucleic acids Proteins 0.000 claims description 178
- 239000000523 sample Substances 0.000 claims description 169
- 239000002773 nucleotide Substances 0.000 claims description 115
- 125000003729 nucleotide group Chemical group 0.000 claims description 115
- 206010012601 diabetes mellitus Diseases 0.000 claims description 72
- 230000002068 genetic effect Effects 0.000 claims description 70
- 102220000417 rs7756992 Human genes 0.000 claims description 67
- 238000001514 detection method Methods 0.000 claims description 65
- 108091034117 Oligonucleotide Proteins 0.000 claims description 47
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 46
- 239000002751 oligonucleotide probe Substances 0.000 claims description 46
- 102210017388 rs6931514 Human genes 0.000 claims description 42
- 238000004458 analytical method Methods 0.000 claims description 41
- 239000008103 glucose Substances 0.000 claims description 41
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 40
- 238000009396 hybridization Methods 0.000 claims description 35
- 102210021749 rs10440833 Human genes 0.000 claims description 34
- 102210022093 rs9356744 Human genes 0.000 claims description 34
- 230000000295 complement effect Effects 0.000 claims description 33
- 102210036915 rs9368222 Human genes 0.000 claims description 31
- 238000003556 assay Methods 0.000 claims description 30
- 239000003623 enhancer Substances 0.000 claims description 28
- 239000012634 fragment Substances 0.000 claims description 28
- 230000002829 reductive effect Effects 0.000 claims description 28
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 25
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 25
- 230000035945 sensitivity Effects 0.000 claims description 25
- 238000003205 genotyping method Methods 0.000 claims description 24
- 102210009355 rs6583826 Human genes 0.000 claims description 24
- 239000003153 chemical reaction reagent Substances 0.000 claims description 22
- 238000003752 polymerase chain reaction Methods 0.000 claims description 22
- 230000004044 response Effects 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 230000006362 insulin response pathway Effects 0.000 claims description 19
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 17
- 238000012216 screening Methods 0.000 claims description 16
- 239000013068 control sample Substances 0.000 claims description 15
- 230000001681 protective effect Effects 0.000 claims description 14
- 238000012502 risk assessment Methods 0.000 claims description 13
- 230000003321 amplification Effects 0.000 claims description 12
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 12
- 238000012544 monitoring process Methods 0.000 claims description 11
- 108010042407 Endonucleases Proteins 0.000 claims description 9
- 238000004393 prognosis Methods 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 8
- 101100099162 Homo sapiens TCF7L2 gene Proteins 0.000 claims description 7
- 238000005259 measurement Methods 0.000 claims description 7
- 238000012163 sequencing technique Methods 0.000 claims description 7
- 238000011277 treatment modality Methods 0.000 claims description 7
- 102000054767 gene variant Human genes 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000000090 biomarker Substances 0.000 claims description 4
- 238000010791 quenching Methods 0.000 claims description 4
- 230000000171 quenching effect Effects 0.000 claims description 4
- 238000011325 biochemical measurement Methods 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 3
- 238000001712 DNA sequencing Methods 0.000 claims description 2
- 108010010677 Phosphodiesterase I Proteins 0.000 claims description 2
- 102000004533 Endonucleases Human genes 0.000 claims 3
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 136
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 62
- 201000010099 disease Diseases 0.000 abstract description 61
- 238000012098 association analyses Methods 0.000 abstract description 12
- 238000013459 approach Methods 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 4
- 230000003449 preventive effect Effects 0.000 abstract description 3
- 230000006806 disease prevention Effects 0.000 abstract description 2
- 230000007310 pathophysiology Effects 0.000 abstract description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 75
- 102000004196 processed proteins & peptides Human genes 0.000 description 72
- 229920001184 polypeptide Polymers 0.000 description 71
- 230000014509 gene expression Effects 0.000 description 64
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 63
- 108020004414 DNA Proteins 0.000 description 62
- 238000012360 testing method Methods 0.000 description 46
- 210000000349 chromosome Anatomy 0.000 description 39
- 102000004169 proteins and genes Human genes 0.000 description 39
- 101710092048 Threonylcarbamoyladenosine tRNA methylthiotransferase Proteins 0.000 description 38
- 229940125396 insulin Drugs 0.000 description 32
- 102000004877 Insulin Human genes 0.000 description 31
- 108090001061 Insulin Proteins 0.000 description 31
- 102100021496 Insulin-degrading enzyme Human genes 0.000 description 31
- 108090000828 Insulysin Proteins 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 31
- 230000000694 effects Effects 0.000 description 27
- 108020004999 messenger RNA Proteins 0.000 description 26
- 239000013615 primer Substances 0.000 description 25
- 239000000047 product Substances 0.000 description 24
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 23
- 102100035310 Threonylcarbamoyladenosine tRNA methylthiotransferase Human genes 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- 101001021503 Homo sapiens Hematopoietically-expressed homeobox protein HHEX Proteins 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 230000006870 function Effects 0.000 description 20
- 230000006798 recombination Effects 0.000 description 20
- 238000005215 recombination Methods 0.000 description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 102100035961 Hematopoietically-expressed homeobox protein HHEX Human genes 0.000 description 17
- 230000003914 insulin secretion Effects 0.000 description 17
- 108091092878 Microsatellite Proteins 0.000 description 16
- 230000008859 change Effects 0.000 description 16
- 230000000875 corresponding effect Effects 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 16
- 102000013717 Cyclin-Dependent Kinase 5 Human genes 0.000 description 15
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 15
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 15
- 150000001413 amino acids Chemical group 0.000 description 15
- 230000000692 anti-sense effect Effects 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 230000018109 developmental process Effects 0.000 description 15
- 230000009368 gene silencing by RNA Effects 0.000 description 15
- 239000004055 small Interfering RNA Substances 0.000 description 15
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 14
- 239000002853 nucleic acid probe Substances 0.000 description 14
- 101001008952 Dictyostelium discoideum Kinesin-related protein 11 Proteins 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 101001008953 Homo sapiens Kinesin-like protein KIF11 Proteins 0.000 description 13
- 102100027629 Kinesin-like protein KIF11 Human genes 0.000 description 13
- 238000011161 development Methods 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- 230000035772 mutation Effects 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 108020004459 Small interfering RNA Proteins 0.000 description 12
- 239000000969 carrier Substances 0.000 description 12
- 230000015556 catabolic process Effects 0.000 description 12
- 102220000423 rs13266634 Human genes 0.000 description 12
- 108010021466 Mutant Proteins Proteins 0.000 description 11
- 102000008300 Mutant Proteins Human genes 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- 238000006731 degradation reaction Methods 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 10
- 102100038450 Mitochondrial tRNA methylthiotransferase CDK5RAP1 Human genes 0.000 description 10
- 101710118984 Mitochondrial tRNA methylthiotransferase CDK5RAP1 Proteins 0.000 description 10
- 108700024394 Exon Proteins 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 208000008589 Obesity Diseases 0.000 description 8
- 108091093037 Peptide nucleic acid Proteins 0.000 description 8
- 230000002596 correlated effect Effects 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 235000020824 obesity Nutrition 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 239000002987 primer (paints) Substances 0.000 description 8
- 238000010561 standard procedure Methods 0.000 description 8
- 206010022489 Insulin Resistance Diseases 0.000 description 7
- 238000004422 calculation algorithm Methods 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 239000002679 microRNA Substances 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 229940123208 Biguanide Drugs 0.000 description 6
- 102100031780 Endonuclease Human genes 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 101000596771 Homo sapiens Transcription factor 7-like 2 Proteins 0.000 description 6
- 108091027967 Small hairpin RNA Proteins 0.000 description 6
- 229940100389 Sulfonylurea Drugs 0.000 description 6
- 201000001421 hyperglycemia Diseases 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000012552 review Methods 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 229940123464 Thiazolidinedione Drugs 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 239000003472 antidiabetic agent Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 238000007410 oral glucose tolerance test Methods 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 101150097704 HHEX gene Proteins 0.000 description 4
- 101001045740 Homo sapiens Hepatocyte nuclear factor 4-alpha Proteins 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 102100035101 Transcription factor 7-like 2 Human genes 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000007876 drug discovery Methods 0.000 description 4
- 230000000667 effect on insulin Effects 0.000 description 4
- 238000003197 gene knockdown Methods 0.000 description 4
- 230000030279 gene silencing Effects 0.000 description 4
- 238000012252 genetic analysis Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 229950004994 meglitinide Drugs 0.000 description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 4
- 229960003105 metformin Drugs 0.000 description 4
- 108091070501 miRNA Proteins 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 238000002966 oligonucleotide array Methods 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 230000015031 pancreas development Effects 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 102220056657 rs730880424 Human genes 0.000 description 4
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 4
- 150000001467 thiazolidinediones Chemical class 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 238000000729 Fisher's exact test Methods 0.000 description 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 3
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 3
- 238000003657 Likelihood-ratio test Methods 0.000 description 3
- 238000007476 Maximum Likelihood Methods 0.000 description 3
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000000074 antisense oligonucleotide Substances 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 150000004283 biguanides Chemical class 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000002981 blocking agent Substances 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- 238000012226 gene silencing method Methods 0.000 description 3
- 230000009395 genetic defect Effects 0.000 description 3
- -1 glimeprid Chemical compound 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 102210030976 rs7903146 Human genes 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
- 102000004007 Calpain-10 Human genes 0.000 description 2
- 108090000451 Calpain-10 Proteins 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 108010036364 Deoxyribonuclease IV (Phage T4-Induced) Proteins 0.000 description 2
- 102100023374 Forkhead box protein M1 Human genes 0.000 description 2
- 208000034951 Genetic Translocation Diseases 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 102100022054 Hepatocyte nuclear factor 4-alpha Human genes 0.000 description 2
- 101000614701 Homo sapiens ATP-sensitive inward rectifier potassium channel 11 Proteins 0.000 description 2
- 101000907578 Homo sapiens Forkhead box protein M1 Proteins 0.000 description 2
- 101001047190 Homo sapiens Inward rectifier potassium channel 16 Proteins 0.000 description 2
- 101000944277 Homo sapiens Inward rectifier potassium channel 2 Proteins 0.000 description 2
- 101150087317 IDE gene Proteins 0.000 description 2
- 206010052341 Impaired insulin secretion Diseases 0.000 description 2
- 102100022774 Inward rectifier potassium channel 16 Human genes 0.000 description 2
- 102100033114 Inward rectifier potassium channel 2 Human genes 0.000 description 2
- 102000019293 Kinesin-like proteins Human genes 0.000 description 2
- 108050006659 Kinesin-like proteins Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 208000001280 Prediabetic State Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 241000201776 Steno Species 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000013814 Wnt Human genes 0.000 description 2
- 108050003627 Wnt Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 238000012197 amplification kit Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000024321 chromosome segregation Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 238000013412 genome amplification Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 239000003538 oral antidiabetic agent Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000002974 pharmacogenomic effect Effects 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 239000012857 radioactive material Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 102220002833 rs12255372 Human genes 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 230000004960 subcellular localization Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 101150000874 11 gene Proteins 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- IRNJSRAGRIZIHD-UHFFFAOYSA-N 5-[[4-[2-(5-ethyl-2-pyridinyl)-2-oxoethoxy]phenyl]methyl]thiazolidine-2,4-dione Chemical compound N1=CC(CC)=CC=C1C(=O)COC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 IRNJSRAGRIZIHD-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 102100021177 ATP-sensitive inward rectifier potassium channel 11 Human genes 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 244000175448 Citrus madurensis Species 0.000 description 1
- 235000004332 Citrus madurensis Nutrition 0.000 description 1
- 235000007438 Citrus mitis Nutrition 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102100022123 Hepatocyte nuclear factor 1-beta Human genes 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 101001045758 Homo sapiens Hepatocyte nuclear factor 1-beta Proteins 0.000 description 1
- 101000599779 Homo sapiens Insulin-like growth factor 2 mRNA-binding protein 2 Proteins 0.000 description 1
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 1
- 101000976959 Homo sapiens Transcription factor 4 Proteins 0.000 description 1
- 101000904150 Homo sapiens Transcription factor E2F3 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100037919 Insulin-like growth factor 2 mRNA-binding protein 2 Human genes 0.000 description 1
- 102000017792 KCNJ11 Human genes 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 241000997826 Melanocetus johnsonii Species 0.000 description 1
- 101100198353 Mus musculus Rnasel gene Proteins 0.000 description 1
- 102000010645 MutS Proteins Human genes 0.000 description 1
- 108010038272 MutS Proteins Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241000364051 Pima Species 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000035554 Proglucagon Human genes 0.000 description 1
- 108010058003 Proglucagon Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 208000030555 Pygmy Diseases 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 108700011001 Transcription Factor 7-Like 2 Proteins 0.000 description 1
- 102100024027 Transcription factor E2F3 Human genes 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000004156 Wnt signaling pathway Effects 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 108091006550 Zinc transporters Proteins 0.000 description 1
- DUDJTRNGXIUJEB-UHFFFAOYSA-N [N].NCC(O)=O Chemical group [N].NCC(O)=O DUDJTRNGXIUJEB-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 238000007844 allele-specific PCR Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000012093 association test Methods 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000025938 carbohydrate utilization Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 1
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000003158 enteroendocrine cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000011545 laboratory measurement Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000036179 multiple type 2 exostoses Diseases 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 101150006569 rpsR gene Proteins 0.000 description 1
- 102210042528 rs1111875 Human genes 0.000 description 1
- 102210041822 rs12243326 Human genes 0.000 description 1
- 102200010892 rs1805192 Human genes 0.000 description 1
- 102220000965 rs4402960 Human genes 0.000 description 1
- 102210021890 rs4430796 Human genes 0.000 description 1
- 102220048996 rs5215 Human genes 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000009752 translational inhibition Effects 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IS8572 | 2006-11-30 | ||
| IS8630 | 2007-04-04 | ||
| PCT/IS2007/000020 WO2008065682A2 (en) | 2006-11-30 | 2007-11-30 | Genetic susceptibility variants of type 2 diabetes mellitus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013264999A Division JP2014097060A (ja) | 2006-11-30 | 2013-12-24 | ２型糖尿病の遺伝的感受性変異体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010510804A true JP2010510804A (ja) | 2010-04-08 |
| JP2010510804A5 JP2010510804A5 (enExample) | 2011-01-27 |
Family
ID=39102918
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009538856A Pending JP2010510804A (ja) | 2006-11-30 | 2007-11-30 | ２型糖尿病の遺伝的感受性変異体 |
| JP2013264999A Pending JP2014097060A (ja) | 2006-11-30 | 2013-12-24 | ２型糖尿病の遺伝的感受性変異体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013264999A Pending JP2014097060A (ja) | 2006-11-30 | 2013-12-24 | ２型糖尿病の遺伝的感受性変異体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100086921A1 (enExample) |
| EP (1) | EP2099937A2 (enExample) |
| JP (2) | JP2010510804A (enExample) |
| KR (1) | KR20090087486A (enExample) |
| AU (1) | AU2007326838B9 (enExample) |
| CA (1) | CA2683909A1 (enExample) |
| SG (1) | SG177148A1 (enExample) |
| WO (1) | WO2008065682A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013021994A (ja) * | 2011-07-25 | 2013-02-04 | Institute Of Physical & Chemical Research | 第６染色体短腕２２領域または第９染色体長腕２１領域の一塩基多型に基づく肥満の検査方法 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008065544A2 (en) * | 2006-09-11 | 2008-06-05 | Mcgill University | Genetic predictors of risk for type 2 diabetes mellitus |
| EP2451975A4 (en) * | 2009-05-08 | 2013-08-14 | Decode Genetics Ehf | GENETIC VARIANTS CONTRIBUTING TO A RISK OF PROSTATE CANCER |
| US8796182B2 (en) | 2009-07-10 | 2014-08-05 | Decode Genetics Ehf. | Genetic markers associated with risk of diabetes mellitus |
| CN105188692A (zh) * | 2013-03-29 | 2015-12-23 | 国立大学法人熊本大学 | 2型糖尿病治疗剂 |
| KR101459057B1 (ko) * | 2014-02-27 | 2014-11-12 | 서울대학교병원 (분사무소) | 임신성 당뇨병 이후 제2형 당뇨병 발병 예측 방법 |
| CN110218781B (zh) * | 2019-04-23 | 2023-03-31 | 河北医科大学 | 21个微单倍型位点的复合扩增体系、下一代测序分型试剂盒及分型方法 |
| WO2022203533A1 (ru) * | 2021-03-25 | 2022-09-29 | Владимир Валерьевич ВОЛОБУЕВ | Способ оценки предрасположенности к различным формам сахарного диабета 2го типа |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005108613A2 (en) * | 2004-04-07 | 2005-11-17 | Decode Genetics Ehf. | Human type ii diabetes gene-kv channel-interacting protein (kchip1) located on chromosome 5 |
| WO2006008342A1 (en) * | 2004-07-16 | 2006-01-26 | Oy Jurilab Ltd | Method for detecting the risk of and for treatment of type 2 diabetes |
| JP2006506988A (ja) * | 2002-11-01 | 2006-03-02 | デコード ジェネティクス イーエッチエフ． | 染色体５ｑ３５に位置したヒトＩＩ型糖尿病遺伝子−ＳＬＩＴ−３ |
| WO2006088308A1 (en) * | 2005-02-15 | 2006-08-24 | Samsung Electronics Co., Ltd. | Method of diagnosing type ii diabetes mellitus using multilocus marker, polynucleotide including marker associated with type ii diabetes mellitus, and microarray and diagnostic kit including the polynucleotide |
| WO2006104812A2 (en) * | 2005-03-25 | 2006-10-05 | Novartis Ag | Biomarkers for pharmacogenetic diagnosis of type 2 diabetes |
| JP2006296270A (ja) * | 2005-04-19 | 2006-11-02 | Univ Of Tokyo | Ｐｒｋａａ２遺伝子多型による２型糖尿病発症素因の検出方法 |
| JP2008546403A (ja) * | 2005-06-20 | 2008-12-25 | デコード・ジェネティクス・イーエイチエフ | ２型糖尿病のリスクの診断マーカーとしてのｔｃｆ７ｌ２遺伝子中の遺伝子変異体 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| JPS60501339A (ja) * | 1983-01-10 | 1985-08-22 | ジエン−プロ−ブ インコ−ポレィテッド | 生物を検出、同定又は定量する方法およびキット |
| US5288611A (en) * | 1983-01-10 | 1994-02-22 | Gen-Probe Incorporated | Method for detecting, identifying, and quantitating organisms and viruses |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5143854A (en) * | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5424186A (en) * | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| US5288644A (en) * | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5384261A (en) * | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| US5858659A (en) * | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| US5837832A (en) * | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| EP1080209A2 (en) * | 1998-10-21 | 2001-03-07 | Arch Development Corporation | Methods of treatment of type 2 diabetes |
| US20030092019A1 (en) * | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
-
2007
- 2007-11-30 US US12/442,233 patent/US20100086921A1/en not_active Abandoned
- 2007-11-30 SG SG2011088325A patent/SG177148A1/en unknown
- 2007-11-30 AU AU2007326838A patent/AU2007326838B9/en not_active Ceased
- 2007-11-30 WO PCT/IS2007/000020 patent/WO2008065682A2/en not_active Ceased
- 2007-11-30 JP JP2009538856A patent/JP2010510804A/ja active Pending
- 2007-11-30 EP EP07827612A patent/EP2099937A2/en not_active Withdrawn
- 2007-11-30 KR KR1020097013458A patent/KR20090087486A/ko not_active Ceased
- 2007-11-30 CA CA002683909A patent/CA2683909A1/en not_active Abandoned
-
2013
- 2013-12-24 JP JP2013264999A patent/JP2014097060A/ja active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006506988A (ja) * | 2002-11-01 | 2006-03-02 | デコード ジェネティクス イーエッチエフ． | 染色体５ｑ３５に位置したヒトＩＩ型糖尿病遺伝子−ＳＬＩＴ−３ |
| WO2005108613A2 (en) * | 2004-04-07 | 2005-11-17 | Decode Genetics Ehf. | Human type ii diabetes gene-kv channel-interacting protein (kchip1) located on chromosome 5 |
| WO2006008342A1 (en) * | 2004-07-16 | 2006-01-26 | Oy Jurilab Ltd | Method for detecting the risk of and for treatment of type 2 diabetes |
| WO2006088308A1 (en) * | 2005-02-15 | 2006-08-24 | Samsung Electronics Co., Ltd. | Method of diagnosing type ii diabetes mellitus using multilocus marker, polynucleotide including marker associated with type ii diabetes mellitus, and microarray and diagnostic kit including the polynucleotide |
| WO2006104812A2 (en) * | 2005-03-25 | 2006-10-05 | Novartis Ag | Biomarkers for pharmacogenetic diagnosis of type 2 diabetes |
| JP2006296270A (ja) * | 2005-04-19 | 2006-11-02 | Univ Of Tokyo | Ｐｒｋａａ２遺伝子多型による２型糖尿病発症素因の検出方法 |
| JP2008546403A (ja) * | 2005-06-20 | 2008-12-25 | デコード・ジェネティクス・イーエイチエフ | ２型糖尿病のリスクの診断マーカーとしてのｔｃｆ７ｌ２遺伝子中の遺伝子変異体 |
Non-Patent Citations (3)
| Title |
|---|
| JPN5009019284; ＭＡＥＤＡ， Ｓ． ｅｔ ａｌ．: ＪＯＵＲＮＡＬ ＯＦ ＨＵＭＡＮ ＧＥＮＥＴＩＣＳ Ｖｏｌ．５０， Ｎｏ．６, 20050601, Ｐ．２８３-２９２, ＳＰＲＩＮＧＥＲ-ＶＥＲＬＡＧ * |
| JPN5009019286; ＭＯＲＩＴＡＮＩ， Ｍ． ｅｔ ａｌ．: ＧＥＮＯＭＩＣＳ Ｖｏｌ．８８， Ｎｏ．６, 20061116, Ｐ．７１９-７３０, ＡＣＡＤＥＭＩＣ ＰＲＥＳＳ * |
| JPN6012058646; ＫＡＴＯ， Ｈ． ｅｔ ａｌ．: ＧＥＮＯＭＩＣＳ Ｖｏｌ．８７， Ｎｏ．４, 200604, Ｐ．４４６-４５８ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013021994A (ja) * | 2011-07-25 | 2013-02-04 | Institute Of Physical & Chemical Research | 第６染色体短腕２２領域または第９染色体長腕２１領域の一塩基多型に基づく肥満の検査方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2099937A2 (en) | 2009-09-16 |
| AU2007326838B9 (en) | 2014-02-13 |
| US20100086921A1 (en) | 2010-04-08 |
| WO2008065682A3 (en) | 2008-10-16 |
| AU2007326838B2 (en) | 2014-01-30 |
| JP2014097060A (ja) | 2014-05-29 |
| WO2008065682A2 (en) | 2008-06-05 |
| AU2007326838A1 (en) | 2008-06-05 |
| CA2683909A1 (en) | 2008-06-05 |
| SG177148A1 (en) | 2012-01-30 |
| KR20090087486A (ko) | 2009-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5631000B2 (ja) | Ｃｈｒ８ｑ２４．２１上の癌感受性変異体 | |
| US8865400B2 (en) | Genetic variants contributing to risk of prostate cancer | |
| CN102144036B (zh) | 用于乳腺癌风险评估的遗传变型 | |
| US8796182B2 (en) | Genetic markers associated with risk of diabetes mellitus | |
| EP2535425A1 (en) | Variantes génétiques sur les chr 10q26 utilisées comme marqueurs dans l'évaluation, le diagnostic, le pronostic et le traitement d'un risque de cancer du sein | |
| EP2527466A2 (en) | Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
| CA2729931A1 (en) | Genetic variants predictive of cancer risk in humans | |
| JP2014097060A (ja) | ２型糖尿病の遺伝的感受性変異体 | |
| US20100047807A1 (en) | Genetic variants associated with periodic limb movements and restless legs syndrome | |
| NZ577804A (en) | Genetic susceptibility variants of type 2 diabetes mellitus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101130 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101130 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121108 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130204 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130212 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130405 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130412 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130508 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130821 |